Please login to the form below

Not currently logged in
Email:
Password:

DMD

This page shows the latest DMD news and features for those working in and with pharma, biotech and healthcare.

Ex-Pharmacyclics CEO invests $25m in Summit

Ex-Pharmacyclics CEO invests $25m in Summit

It’s also a boost to the UK company after the disappointment of its recent failed programme in Duchenne muscular dystrophy (DMD), which prompted its re-focusing as an anti-infectives

Latest news

  • Entering the era of digital trials Entering the era of digital trials

    A version of the phenomenon affects trials in muscle disorders such as Duchenne muscular dystrophy (DMD). ... One study found kids with DMD walked 11% further if they were offered $50 (£39) to beat their previous distance.

  • Duchenne UK backs Evox dystrophin delivery project Duchenne UK backs Evox dystrophin delivery project

    large-molecule delivery technology in Duchenne muscular dystrophy (DMD). ... The funding round will help Evox carry out preclinical studies on dystrophin-bearing exosomes, to see if the approach can be an alternative to other emerging DMD therapies that

  • Pfizer abandons antibody for Duchenne Pfizer abandons antibody for Duchenne

    Latest to fail in myostatin inhibitor class. Pfizer has halted development of its Duchenne muscular dystrophy (DMD) candidate domagrozumab on disappointing results in a mid-stage efficacy trial. ... Pfizer still has an iron in the DMD fire, in the form

  • Mallinckrodt doses first patient in muscular dystrophy trial Mallinckrodt doses first patient in muscular dystrophy trial

    DMD is caused by a lack of functional dystrophin protein, which assists in keeping muscles healthy. ... Mallinckrodt’s step forward comes shortly after another UK biotech, Summit Therapeutics, saw its shares go into freefall in June after its DMD

  • Summit plunges after Duchenne disappointment Summit plunges after Duchenne disappointment

    Shares in UK biotech Summit Therapeutics plunged 80% after its treatment for Duchenne muscular dystrophy (DMD) failed in phase II trials. ... Nevertheless Glyn Edwards warned that cutbacks at the company would now be inevitable after losing its DMD

More from news
Approximately 8 fully matching, plus 32 partially matching documents found.

Latest Intelligence

  • Tackling a formidable foe Tackling a formidable foe

    Like other DMDs, metal exposure should be avoided,” adds Ben- Amor, who has been involved in MS research and business operations for 20 years.

  • Pharma deals during November 2014 Pharma deals during November 2014

    additional $160m more in near-term milestones if drisapersen, the late-stage drug for Duchenne muscular dystrophy (DMD), secures “early” approval. ... $20.31 before settling at around $19.00.  Prosensa has been busy since drisapersen failed a

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Catabasis hires Rick Modi as its chief business officer Catabasis hires Rick Modi as its chief business officer

    We look forward to leveraging his capabilities as we advance our clinical development pipeline, particularly CAT-1004 for Duchenne muscular dystrophy (DMD), and our lipid programmes, CAT-2003 and CAT-2054.”. ... we seek to bring disease-modifying

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Solaris Health looks at the gene therapy revolution

    for instance to treat haemophilia, rare ophthalmic disorders and for Duchenne muscular dystrophy/DMD), genetic therapies are likely to represent a revolution in medicine over the coming years. ... However, in most areas where genetic treatments are being

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides market research, insights, and scientific and medical communication services to the pharmaceutical industry across the...

Latest intelligence

The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch
...

Infographics